Mikael Dolsten is president of Worldwide Research and Development at Pfizer, where he is a member of the executive leadership team and the Portfolio Strategy and Investment Committee. Prior to joining Pfizer in 2009, he was president of Wyeth Research. Dolsten began his career at University of Lund in Sweden, where he was an adjunct professor in tumor immunology. A fellow of the New York Academy of Medicine, he serves on multiple external boards and committees and is a named inventor on several patents. He has published approximately 150 articles in international journals, with contributions in areas such as molecular cell biology, immunology and oncology.
Previously
Individual genetic makeup and the genetic signature of diseases vary tremendously, but the goal of matching them with custom-tailored treatment remains in its infancy. Precisi...